Biogen Inc (BIIB)
213.46
-2.67
(-1.24%)
USD |
NASDAQ |
May 02, 16:00
213.40
-0.06
(-0.03%)
After-Hours: 16:37
Biogen Cash from Financing (Quarterly): -439.60M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -439.60M |
| December 31, 2023 | -646.10M |
| September 30, 2023 | 848.60M |
| June 30, 2023 | -9.80M |
| March 31, 2023 | -43.40M |
| December 31, 2022 | -7.40M |
| September 30, 2022 | -1.252B |
| June 30, 2022 | -471.50M |
| March 31, 2022 | -16.50M |
| December 31, 2021 | 9.80M |
| September 30, 2021 | -746.50M |
| June 30, 2021 | -564.50M |
| March 31, 2021 | -785.00M |
| December 31, 2020 | -401.10M |
| September 30, 2020 | -1.313B |
| June 30, 2020 | -1.313B |
| March 31, 2020 | -2.245B |
| December 31, 2019 | -2.116B |
| September 30, 2019 | -689.00M |
| June 30, 2019 | -2.376B |
| March 31, 2019 | -679.30M |
| December 31, 2018 | -1.437B |
| September 30, 2018 | 25.10M |
| June 30, 2018 | -2.792B |
| March 31, 2018 | -268.60M |
| Date | Value |
|---|---|
| December 31, 2017 | -708.10M |
| September 30, 2017 | -19.50M |
| June 30, 2017 | -751.00M |
| March 31, 2017 | -901.40M |
| December 31, 2016 | -726.50M |
| September 30, 2016 | -305.30M |
| June 30, 2016 | -15.80M |
| March 31, 2016 | -5.00M |
| December 31, 2015 | -2.202B |
| September 30, 2015 | 2.908B |
| June 30, 2015 | -3.60M |
| March 31, 2015 | 80.80M |
| December 31, 2014 | -513.29M |
| September 30, 2014 | -35.12M |
| June 30, 2014 | -322.36M |
| March 31, 2014 | 114.88M |
| December 31, 2013 | 11.21M |
| September 30, 2013 | -318.52M |
| June 30, 2013 | -170.76M |
| March 31, 2013 | -238.42M |
| December 31, 2012 | -15.52M |
| September 30, 2012 | -28.25M |
| June 30, 2012 | -417.44M |
| March 31, 2012 | -416.26M |
| December 31, 2011 | -142.81M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.376B
Minimum
Jun 2019
848.60M
Maximum
Sep 2023
-728.88M
Average
-605.30M
Median
Cash from Financing (Quarterly) Benchmarks
| Eli Lilly and Co | -311.30M |
| Bristol-Myers Squibb Co | 14.64B |
| Gilead Sciences Inc | -1.361B |
| AbbVie Inc | -4.449B |
| Sage Therapeutics Inc | 1.557M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 553.20M |
| Cash from Investing (Quarterly) | -66.00M |
| Free Cash Flow | 1.284B |
| Free Cash Flow Per Share (Quarterly) | 2.963 |
| Free Cash Flow to Equity (Quarterly) | 830.40M |
| Free Cash Flow to Firm (Quarterly) | 476.14M |
| Free Cash Flow Yield | 4.13% |